Etoposide with or without mannitol for the treatment of recurrent or primarily unresponsive brain tumors: A Children's Cancer Group Study, CCG-9881

Journal of Neuro-Oncology

Volumn 45, Issue 1, 1999, Pages 47-54

  Kobrinsky, Nathan L ^a,i   Packer, Roger J ^b   Boyett, James M ^c   Stanley, Philip ^d   Shiminski Maher, Tania ^e   Allen, Jeffrey C ^e   Garvin, James H ^f   Stewart, David J ^g   Finlay, Jonathan L ^h  

^a MeritCare Roger Maris Cancer Center   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

^e BETH ISRAEL MEDICAL CENTER   (United States)

^f ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

^g OTTAWA REGIONAL CANCER CENTRE   (Canada)

^h NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

ⁱ CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

Blood brain barrier; Children; Etoposide; Mannitol; Recurrent brain tumor

Indexed keywords

ETOPOSIDE; MANNITOL;

ADOLESCENT; ADULT; ALLERGY; ARTICLE; ASTROCYTOMA; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BRAIN TUMOR; CHILD; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GASTROINTESTINAL TOXICITY; GLIOMA; HUMAN; INFECTION; LIVER TOXICITY; LUNG TOXICITY; MALE; MEDULLOBLASTOMA; NEPHROTOXICITY; NEUROECTODERM TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT CANCER;

ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CHILD; DRUG THERAPY, COMBINATION; ETOPOSIDE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MANNITOL; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 0033500451     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006333811437     Document Type: Article

References (30)

1. Hainsworth JD, Greco FA: Etoposide: twenty years later [Review]. Ann Oncol 6(4): 325-341, 1995
2. Beauchesne P, Bertrand S, N'guyen MJ, Christianson T, Dore JF, Mornex F, Bonner JA: Etoposide sensitivity of radioresistant human glioma cell lines. Cancer Chemother Pharmacol 41(2): 93-97, 1998
3. Chard RL, Krivit W, Bleyer WA, Hammond D: Phase II study of VP-16-213 in childhood malignant disease: A Childrens Cancer Study Group report. Cancer Treat Rep 63: 1755-1759, 1979
4. Schmoll H: Review of etoposide single-agent activity. Cancer Treat Rev 9 (Suppl A): 21-30, 1982
5. Tirelli U, D'Incalci M, Canetta R, Tumolo S, Franchin G, Veronesi A, Galligioni E, Trovo MG, Rossi C, Grigoletto E: Etoposide (VP-16-213) in malignant brain tumors: A phase II study. J Clin Oncol 2: 432-437, 1984
6. Postmus PE, Holthius JJM, Haaxma-Reiche H, Mulder NH, Vencken LM, van Oort WJ, Sleijfer DT, Sluiter HJ: Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration. J Clin Oncol 2: 215-220, 1984
7. Stewart DJ, Richard MT, Hugenholz H, Dennery JM, Belanger R, Gerin-Lajoie, J, Montetit V, Nundy D, Prior J, Hopkins HS: Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neuro-Oncol 2(2): 133-139, 1984
8. Postmus PE, Mulder NH, Sleijfer DT, Meinesz AF, Vriesendorp R, de Vries EG: High-dose etoposide for refractory malignancies: A phasel study. Cancer Treat Rep 68(2): 1471-1474, 1984
9. Finn GP, Bozek T, Souhami RL, Slevin ML, Thomas DG: High-dose etoposide in the treatment of relapsed primary brain tumors. Cancer Treat Rep 69(6): 603-605, 1985
10. Stewart DJ, Richard MT, Hugenholtz H, Dennery J, Nundy D, Prior J, Monpetit V, Hopkins HS: Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol. J Neuro-Oncol 2(4): 315-324, 1984
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
12. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 34: 585-612, 1976
13. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1-39, 1977
14. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966
15. Cairo MS: The use of ifosfamide, carboplatin, and etoposide in children with solid tumors (Review). Semin Oncol 22(3) Suppl 7: 23-27, 1995
16. Planting AS, van der Burg ME, de Boer-Dennert M, Stoter G, Verweij J: Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors. Ann Oncol 6(2): 190-192, 1995
17. Voute PA, van den Berg H, Behrendt H, Michiels E, de Kraker J: Ifosfamide in the treatment of pediatric malignancies. Semin Oncol 23(3) Suppl 7: 8-11, 1996
18. Ooi K, Ohkubo T, Higashigawa H, Sakurai M: Increased deoxycytidine kinase activity by etoposide in L1210 murine leukemic cells. Biol Pharmaceut Bull 19(10): 1382-1383, 1996
19. Stewart DJ, Nundy D, Maroun JA, Tetreault L, Prior J: Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. Cancer Treat Rep 69(3): 269-273, 1985
20. Lowis SP, Newell DR: Etoposide for the treatment of paediatric tumors: What is the best way to give it? (Review). Europ J Cancer 32A(13): 2291-2297, 1996
21. de Jong RS, Mulder NH, Dijksterhuis D, de Vries EG: Review of current clinical experience with prolonged (oral) etoposide in cancer treatment (Review). Anticancer Res 15(5B): 2319-2330, 1995
22. Postmus PE, Smit EF. Oral therapy for small cell lung cancer (Review). Lung Cancer 12, Suppl 3: S63-S70, 1995
23. Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A, Kun L, Duffner PK, Smith S, Longee D: Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 14(6): 1922-1927, 1996
24. Chamberlain MC, Kormanik PA: Chronic oral VP-16 for recurrent medulloblastoma. Pediatr Neurol 17(3): 230-234, 1997
25. Needle MN, Molloy PT, Geyer JR, Herman-Lui A, Belasco JB, Goldwein JW, Sutton L, Phillips PC: Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 29(1): 28-32, 1997
26. Chamberlain MC: Recurrent cerebellar gliomas: salvage therapy with oral etoposide. J Child Neurol 12(3): 200-204, 1997
27. Chamberlain MC, Grafe MR: Recurrent chiasmatichypothalamic glioma treated with oral etoposide. J Clin Oncol 13(8): 2072-2076, 1995
28. Chamberlain MC: Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch Neurol 54(5): 554-558, 1997
29. Fulton D, Urtasun R, Forsyth P: Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neuro-Oncol 27 (2): 149-155, 1996
30. Finlay JL, Geyer JR, Turski PA, Yates AJ, Boyett JM, Allen JC, Packer RJ: Pre-irradiation chemotherapy in children with high-grade astrocytoma: Tumor response to two cycles of the '8-drugs-in-1-day' regimen. A Childrens Cancer Group study, CCG-945. J Neuro-Oncol 21: 255-265, 1994